Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The provided claim is directly and verbatim supported by the supplied FDA label text for EGATEN indications and age group, with no contradictions identified.
Category Scores
Accurate Statements
EGATEN (triclabendazole) is indicated for the treatment of fascioliasis in patients 6 years of age and older.
Section 1 INDICATIONS AND USAGE: “EGATEN is indicated for the treatment of fascioliasis in patients 6 years of age and older.”
The indication and age group in the claim match the FDA label exactly.
Section 1 INDICATIONS AND USAGE: “EGATEN is indicated for the treatment of fascioliasis in patients 6 years of age and older.”
Unsupported Statements
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
Only an on-label indication statement was evaluated; it is directly supported with no added dosing/safety assertions.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Suggested Improvement